An oral cancer vaccine using Bifidobacterium vector augments combination of anti-PD-1 and anti-CTLA-4 antibodies in mouse renal cell carcinoma model

An oral cancer vaccine using Bifidobacterium vector augments combination of anti-PD-1 and anti-CTLA-4 antibodies in mouse renal cell carcinoma model

Abstract Recently, immune checkpoint inhibitor (ICI) based combination therapies, including anti-PD-1 antibody, nivolumab with anti-CTLA-4 antibody, and ipilimumab have become the primary treatment option for metastatic or unresectable renal cell carcinoma (RCC). However, despite the combination of...

Full description

Bibliographic Details
Main Authors: Hideto Ueki, Koichi Kitagawa, Mako Kato, Shihoko Yanase, Yasuyoshi Okamura, Yukari Bando, Takuto Hara, Tomoaki Terakawa, Junya Furukawa, Yuzo Nakano, Masato Fujisawa, Toshiro Shirakawa
Format: Article
Language:English
Published: Nature Portfolio 2023-06-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-023-37234-6

Internet

https://doi.org/10.1038/s41598-023-37234-6

Similar Items